ClinicalTrials.gg
TerminatedNCT06766435Updated Oct 15, 2026

Evaluation of the Abbott i-STAT TBI Biomarker Test

An interventional study of i-STAT TBI Test in Traumatic Brain Injury, sponsored by Icahn School of Medicine at Mount Sinai. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
Updated Oct 15, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 2 under way, none of them phase 3. Brain Injuries, Traumatic · Icahn School of Medicine at Mount Sinai.

Enrollment
9th of 11
42 · median 77
Started
2025
the only one that year
No phase
9 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 9 with no phase, and was the 10th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

2 of the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, or all of them as a file.
02

Study summary

According to the Centers for Disease Control and Prevention, approximately 200,000 hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not include many TBIs treated only in emergency departments, urgent care, primary care, or that are not evaluated by a clinician. Head CT is a critical component of care for severe TBI, however in mild TBI there is practice variation with a wider risk to benefit estimation for obtaining head CT imaging. Potential disadvantages of head CT include longer Emergency Department (ED) length of stay (LOS), higher costs, and diagnostic radiation exposure. The i-STAT TBI test is a panel of in vitro diagnostic immunoassays for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood and a semi-quantitative interpretation of test results derived from these measurements, using the i-STAT Alinity instrument. This biomarker test is cleared for use in adults with mild TBI (Glasgow Coma Scale 13-15) within 24 hours of injury, to aid in determining the need for head CT imaging. Currently, CT head imaging for adults with suspected mild TBI is obtained based on clinicians' usual practice patterns and beliefs about patient expectations. Prior research has demonstrated the blood TBI test may reduce unnecessary CT scans by up to 40%, however the impact on head CT ordering has not yet been studied prospectively. It is important to understand the extent to which a negative TBI biomarker result empowers a clinician to cancel a previously ordered head CT. Given that adult patients with mild TBI often present to EDs, which have access to CT scanners, this is a key setting to assess real-world impact of the i-STAT TBI test on CT head utilization.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Point of Care Testing
  • Emergency Care
  • Clinical Decision Making
  • Head Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Head injury within 24 hours of research blood collection
  • CT head ordered as part of routine care, not yet completed.
  • Glasgow Coma Scale (GCS) 13 - 15

Exclusion criteria

Exclusion Criteria:

  • Unknown whether head injury occurred, and signs of head injury are absent
  • Previously enrolled in this study in the past 30 days
  • Prisoner or in police custody or known pregnancy
  • Suspected current ischemic or hemorrhagic stroke
  • Suspected open or depressed skull fracture, or signs of skull base fracture
  • History of multiple sclerosis
  • Venipuncture not feasible
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Notification Arm (Abbott iSTAT TBI test)

    The ED clinicians caring for the enrolled patient, along with the patient, receive the TBI blood test result with just-in-time education on the TBI test to aid in clinical decision making.

    Device: i-STAT TBI Test

  • No intervention
    Non-Notification Arm (Control)

    Clinicians and enrolled patients do not receive the TBI blood test result.

Interventions

  • Devicei-STAT TBI Test

    The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.

    Also known as: Abbott iSTAT Alinity

06

What researchers measure

Primary outcomes

  1. Number of Head CT scans canceled

    Number of head CTs canceled in patients not on anticoagulants as measurement of percentage of reduction in the number of canceled head CTs out of total head CTs ordered (total number and percentage)

    Time frame: Within 24 hours of Traumatic Brain Injury

Secondary outcomes

  1. Subset of Number of Head CT scans completed

    If the i-STAT TBI test results had been strictly adhered to by clinicians, subset of negative i-STAT TBI test results, Potential reduction in the number of completed head CTs (canceled) out of total head CTs ordered (total number and percentage)

    Time frame: Within 24 hours of Traumatic Brain Injury

  2. ED Length of Stay

    Length of stay for the Emergency Department patient encounter

    Time frame: Day 1 after patient ED care visit has ended

  3. Number of cancellations of head CT scan order in patients on anticoagulants

    Number of cancellations in head CTs in patients on anticoagulation

    Time frame: Day 1 after patient ED care visit has ended

  4. Patient Satisfaction Scale

    Assessment of patient satisfaction with care during ED visit. Full scale from 1 (worst care possible) to 10 (best care possible)

    Time frame: At 14 days after ED visit

  5. Number of head CT scans completed

    Number of head CT scans completed for patients within 14 days after index ED visit

    Time frame: At 14 days after ED visit

  6. Stress of Uncertainty Scale (SUS)

    Clinicians vary in their use of diagnostic testing and treatments, and stress of uncertainty may be one explanation for this variation. The stress of uncertainty scale measures clinician tolerance of uncertainty during patient care. SUS scores range from 15-90 with a higher score indicating greater fear of uncertainty.

    Time frame: Day 1 during patient ED care visit

  7. Malpractice Fear Scale (MFS) Scores

    Malpractice Fear Scale (MFS) scores. MFS scores range from 6 to 36 with a higher score indicating greater fear of malpractice.

    Time frame: Day 1 during patient ED care visit

  8. Whole blood concentrations of GFAP (glial fibrillary acidic protein)

    Whole blood concentrations for GFAP on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.

    Time frame: Day 1 during patient ED care visit

  9. Whole blood concentrations of UCH-L1 (ubiquitin C-terminal hydrolase L1)

    Whole blood concentrations for UCH-L1 on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.

    Time frame: Day 1 during patient ED care visit

07

Study locations

3 sites
  • Mount Sinai Morningside
    New York, New York 10025, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Mount Sinai West
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD at this time.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Mar 2026, 14 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2025 → Mar 2026 and completion Oct 2025 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2025
First posted
Jan 9, 2025
StartActual
Jan 30, 2025
Primary completionActual
Mar 30, 2026was Sep 2025
CompletionActual
May 30, 2026was Oct 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
changed Oct 15, 2026
Primary completion
Sep 2025→Mar 30, 2026 (actual)
Oct 15, 2026
Study completion
Oct 2025→May 30, 2026 (actual)
Oct 15, 2026
Enrollment
450 (estimated)→42 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Terminated
    Why stopped Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
    Primary completion Sep 2025→Mar 30, 2026 (now actual)
    Study completion Oct 2025→May 30, 2026 (now actual)
    Enrollment 450 (estimated)→42 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06766435
Responsible party
Shameeke Taylor (Assistant Professor of Emergency Medicine, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 9, 2025
Start date
Jan 30, 2025
Primary completion
Mar 30, 2026
Completion
May 30, 2026
Last update
Oct 15, 2026

Study contacts

Shameeke Taylor, MD, MPH, MSCR
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion